Mirabegron Competition
A third player has settled and may enter the market, potentially pressuring Lupin's market share and margins.
high · analyst_question
Lupin Ltd — Q4 FY26
Lupin delivered a stellar Q4 FY26 with revenue of ₹7,475 crore (+32% YoY) and EBITDA of ₹2,171 crore (+68% YoY), marking the 15th consecutive quarter of growth.
bullish
high
✓ Verified against BSE filing
Risk Intelligence
Material risks this quarter
Concise cards keep the risk register scannable while preserving evidence-level context in the underlying quarter data.
Risks
Tolvaptan Patent Expiry
Patent expiry in September 2026 could bring generic competition, impacting US revenue.
high · analyst_questionInflationary Pressures
Rising freight and raw material costs due to geopolitical tensions could impact margins, though management has factored this into guidance.
medium · management_commentaryDapagliflozin 505(b)(2) Launch Delay
Challenges in achieving product PK for the Dapagliflozin 505(b)(2) could delay launch beyond FY27.
medium · analyst_question